Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial

Affiliations

¹ Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
² Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.
³ Department of Urology, Rush University Medical Center, Chicago, IL, USA. Electronic address: ricautor@gmail.com.

Editorial

Zhenjie Wu et al. Eur Urol. 2023 Mar.

. 2023 Mar;83(3):297-298.

doi: 10.1016/j.eururo.2022.11.010. Epub 2022 Dec 1.

¹ Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
² Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.
³ Department of Urology, Rush University Medical Center, Chicago, IL, USA. Electronic address: ricautor@gmail.com.

No abstract available

Comment on

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.
Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Pal SK, et al. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099926 Clinical Trial.